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Stenosis is a major cause of failure of hemodialysis vascular
grafts and is primarily caused by neointimal hyperplasia (NH)
at the anastomoses. The objective of this article is to provide
a scientific review of the biology underlying this disorder and
a critical review of the state-of-the-art investigational
preventive strategies in order to stimulate further research in
this exciting area. The histology of the NH shows
myofibroblasts (that are probably derived from adventitial
fibroblasts), extracellular matrices, pro-inflammatory cells
including foreign-body giant cells, a variety of growth factors
and cytokines, and neovasculature. The contributing factors
of the pathogenesis of NH include surgical trauma,
bioincompatibility of the synthetic graft, and the various
mechanical stresses that result from luminal hypertension
and compliance mismatch between the vessel wall and graft.
These mechanical stimuli are focal in nature and may have a
significant influence on the preferential localization of the
NH. Novel mechanical graft designs and local drug delivery
strategies show promise in animal models in preventing graft
NH development. Successful prevention of graft stenosis
would provide a superior alternative to the native fistula as
hemodialysis vascular access.
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ARTERIOVENOUS GRAFTS AS HEMODIALYSIS VASCULAR
ACCESS
The three major forms of vascular access used for chronic
hemodialysis are the native arteriovenous (AV) fistula, the
synthetic AV graft, which is usually made of expanded
polytetrafluoroethylene (ePTFE), and the cuffed, tunneled
central venous catheter. A well-functioning native fistula is
the preferred choice of vascular access because it has the least
long-term complications. The major drawback with the
native fistula is the failure of many new fistulas to develop
into a usable access. The primary failure rate of native fistulas
reported in the literature varies between 20 and 50%.1 A
randomized trial conducted by the National Institutes of
Health-sponsored Dialysis Access Consortium involving 758
patients recently reported a primary failure rate of approxi-
mately 60% at 6 months after the fistula creation. This rate
was unaffected by a 6-week postoperative course of oral
clopidogrel (preliminary unpublished data from the National
Institute of Diabetes and Digestive and Kidney Diseases
Dialysis Access Consortium Fistula Trial). The prevalence of
AV fistula use is higher in Europe and Japan, even though
their primary AV fistula failure rate is comparable with that
in the United States.2–4 In addition, the dialysis blood flow
rates vary among the United States, Europe, and Japan.
Compared with 412 ml/min in the United States, the mean
blood flow rates in Europe and Japan were 300 and 197 ml/
min, respectively,5 which may not be acceptable in many US
dialysis centers.
The high primary failure rate of native fistula has several
consequences. More diagnostic and remedial procedures,
such as fistulography and angioplasty, are performed. Multi-
ple attempts to create fistulas exhaust vascular sites and the
patient’s tolerance. The need for central venous catheters
while waiting for the fistula to mature is prolonged, with
their attendant complications. The initiative of increasing the
rate of native fistula in the United States has apparently led to
increased catheter use. In fact, approximately 50% of patients
begin chronic hemodialysis with a central catheter.6 There are
also long-term complications associated with native fistulas,
such as stenosis, although at lower rates than other forms of
vascular access.7
The prevalence of the AV synthetic graft for hemodialysis
has decreased in the United States in the last few years,
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concomitant with the increase in the use of native fistulas and
catheters. However, synthetic grafts have an advantage in that
they reliably provide high blood flow rates shortly after
placement, as they do not require maturation before use. The
major problem with grafts is stenosis followed by thrombosis
and occlusion, which accounts for approximately 85% of
their failure.8 Early detection and angioplasty of stenosis do
not improve the graft patency (see ‘Treatment using
angioplasty’ section). The successful prevention of stenosis
is therefore essential for the longevity of AV synthetic grafts.
Understanding the mechanisms that lead to stenosis forma-
tion should facilitate the development of such preventive
strategies. This article will review the pathogenesis of
hemodialysis graft stenosis and describe promising strategies
for its prevention.
PATHOLOGY OF HEMODIAYSIS GRAFT STENOSIS
In AV PTFE grafts, stenosis occurs most commonly at the
graft–venous anastomosis, the juxta-anastomotic venous
segments (Figure 1a), and less frequently at the graft–arterial
anastomosis.9–12 Other than the occasional kinking of the
vessel or thrombus partially obstructing the lumen, stenosis
almost always arises from progressive neointimal hyperplasia
(NH). NH tends to form in the ‘shoulder’ region within the
lumen of the graft and in the ‘cushion’ region of the native
vessel (Figure 1b). Stenotic tissues obtained from the
graft–venous anastomosis of human AV ePTFE grafts showed
an abundance of smooth muscle cells (SMC) and/or
myofibroblasts, accumulation of extracellular matrix, neo-
vasculature within the NH and adventitia, and the presence
of a macrophage layer lining the PTFE graft material. Various
growth factors, such as platelet-derived growth factor
(PDGF), basic fibroblast growth factor, and vascular
endothelial growth factor (VEGF), were conspicuous in the
venous NH in patients.13,14 Similar pathology was found at
the venous anastomosis in canine and porcine AV graft
models, as reported by us and others.10,15–17
The proliferation and migration of medial SMCs have
traditionally been considered to be the primary cellular
source in NH.17,18 The potential role of the adventitia has
received attention only recently.16,19,20 Our results in a
porcine AV ePTFE graft model support this notion.16 Cell
proliferation activity was first detected in the adventitia of the
venous anastomosis as early as day 1 after graft implantation
(Figure 2), followed by activities in the media. Cell
proliferation in the neointima increased linearly only after
2 weeks. Most of the proliferating cells were found to express
smooth muscle a-actin, but not smoothelin or smooth
muscle myosin heavy chain by immunohistochemistry, and
were therefore identified as myofibroblasts. Collectively, these
results support the following paradigm. Within hours after
graft placement, adventitial fibroblasts are transformed into
myofibroblasts. These adventitial myofibroblasts then pro-
liferate, and then migrate toward the vessel lumen, where-
upon they deposit extracellular matrix and serve as primary
contributors to NH formation. Investigation of the pathology
of NH in AV grafts has therefore enhanced our understanding
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Figure 1 | Histology of NH at the venous anastomosis in a
porcine ePTFE AV graft model. (a) Cartoon of the gross anatomy
of the graft-venous anastomosis. V is the location of the
cross-section at the anastomosis presented in panel b. (b)
Histological cross-section of the venous anastomosis. NH is found
in the lumen of the graft (shoulder region) and the venous wall
below the graft (cushion region). Reproduced with permission
from Li et al.16
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Figure 2 | Longitudinal changes in NH index and proliferation
index at the venous anastomosis in a porcine ePTFE AV graft
model over time. Tissues around the venous anastomosis were
obtained from pigs killed at various time points after graft
placement. (a) The proliferation index was calculated as the
number of Ki-67-positive cells found in the native vessel wall in a
given microscopic field divided by the total number of cells in that
same field at  400 original magnification. The proliferation index
in the adventitia (red line) was high in the first 7 days and
decreased thereafter (Po0.0001, day 14, 21, 28, and 49 vs the
respective value at day 1), whereas the index in the neointima
(blue line) became apparent only after day 14 (Po0.0001, day 21,
28, and 49 vs the respective value at day 14). Each data point
represents the mean±s.d. (b) The surface areas of the NH in the
native vessel (cushion region) and inside the graft (shoulder
region); the media and the graft were individually quantified
using computer-assisted planimetry on Elastin von Gieson-stained
slides of the cross-sections. The NH index was calculated as the
neointimal area divided by the sum of the medial area and graft
area. Each bar represents the mean±s.d. NH index increased
linearly with time (r¼ 0.78; Po0.0001). Reproduced with
permission from Li et al.16
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of its pathogenesis and helped to direct the development of
preventive strategies.
PATHOGENESIS OF HEMODIALYSIS GRAFT STENOSIS
The pathogenic mechanisms of NH formation associated
with AV ePTFE graft have not been delineated to the same
extent as that with arterial balloon injury or the arterial–
arterial bypass ePTFE graft. Multiple factors are believed
to contribute to NH in the AV ePTFE graft, including
(a) surgical trauma to the vessel during graft placement;
(b) bioincompatibility of the ePTFE graft material; (c) mechan-
ical factors at the anastomoses; (d) endothelial dysfunction
caused by uremia; and (e) vessel wall damage from repeated
needle punctures for dialysis treatments. The effect of uremia
on NH development has been discussed in other reviews.11,21
This review focuses on the first three factors.
Surgical trauma
Arteriovenous graft placement surgery causes damage to the
intima, media, and adventitia of the vessel. Manipulation
during surgery causes vasospasm, ischemia, and changes in
hemodynamic forces in the vessels, which likely contributes
to NH development.22 Damage to the intima removes the
protective endothelium and exposes the medial SMC directly
to blood flow and other procoagulant and proinflammatory
blood constituents. The intact endothelium secretes prosta-
cyclin (PGI2) and nitric oxide (NO), which are potent
vasodilators.23 These two molecules also inhibit platelet
activation, aggregation, and adhesion to the endothelium or
SMCs, which are likely early events in NH formation. NO
also inhibits SMC proliferation and migration.24,25 In
addition, the adventitial layer is partially removed for
creating the anastomosis during surgery. Depriving the vessel
wall of oxygen and nutrients provided by the adventitial vaso
vasorum has been shown to enhance NH formation.26
Surgical trauma also initiates the recruitment of inflamma-
tory cells that release potent cytokines and promote SMC
migration and proliferation.22
Bioincompatibility
Clinical inflammation, as evident by erythema, edema, and
tenderness in the skin overlying the graft, are common after
surgical placement of grafts, often lasting 7–10 days.
Histologically, macrophages have been observed in large
numbers in the adventitial and medial layers in the
anastomotic tissues from AV ePTFE grafts collected from
patients13,14 and from porcine models of AV graft stenosis.10
In our porcine AV ePTFE graft model, the recruitment of
inflammatory cells, particularly neutrophils and macro-
phages, to the anastomosis occurs very early after graft
placement (Terry CM et al, unpublished data). Another
prominent cell type found at the anastomosis is the foreign-
body giant cell. These cells arise from the fusion of
macrophages and are a product of ‘frustrated phagocytosis’.
Foreign-body giant cells and macrophages are likely im-
portant contributors to NH development in AV grafts,
through the release of proinflammatory mediators such as
cytokines, growth factors, matrix metalloproteinases, and
reactive oxygen species. In support of this notion, the
macrophages and foreign-body giant cells in the NH of
porcine AV grafts have been found to express PDGF, FGF, and
VEGF.13
In addition, we have observed an early and prolonged
accumulation of T-lymphocytes that may participate in the
development of graft NH by releasing cytokines such as
tumor necrosis factor-a. Tumor necrosis factor-a is known to
recruit macrophages, induce matrix metalloproteinases,
and stimulate SMC and fibroblast migration.27,28 However,
T-lymphocytes may also attenuate SMC proliferation, as
athymic rats and T-cell-depleted rats developed greater NH
after balloon-catheter injury than normal animals.29 An
explanation for this potential inhibitory effect is the ability of
T cells to produce interferon-g that can inhibit SMC and
fibroblast proliferation.29–31 However, the role of cytokines
and T cells in NH is complex, and further work is needed to
clarify their role in AV graft hyperplasia.
Dendritic cells, an antigen-presenting cell that activates
T-lymphocytes, have been observed in arterial ePTFE patch
grafts in a sheep model32 and in ePTFE grafts collected from
human patients undergoing revision bypass operations.33–35
The role of dendritic cells in hemodialysis AV graft stenosis
has not yet been reported.
In vitro studies have provided mechanistic insights on how
ePTFE graft bioincompatibility may contribute to NH
development. Conditioned media from human peripheral
blood monocytes exposed to ePTFE graft material induces a
significant increase in rat aortic SMC proliferation.36
Neutralizing antibodies to tumor necrosis factor-a inhibits
this proliferative response, suggesting that tumor necrosis
factor-a plays a role in the mitogenic effect of the ePTFE graft
material per se. Conditioned media obtained from human
peripheral blood monocytes maintained on ePTFE stimu-
lated T-lymphocyte proliferation, probably through the
release of interleukin-1.37 Human macrophages maintained
on ePTFE also released VEGF and angiopoiten-1 and
stimulated the sprouting of capillaries from placental vessel
fragments in vitro.38 Endothelialization of graft material is
hypothesized to be inhibitory to NH development by
tempering proliferation of the underlying SMCs and
fibroblasts on the graft surface. However, angiogenesis also
provides blood supply to the NH. Thus, recruitment and
activation of macrophages and other inflammatory cells by
the ePTFE material may contribute to neovascularization and
thus promote NH development. Successfully addressing the
issue of bioincompatibility of ePTFE grafts could help
alleviate NH development.
Mechanical factors
Several mechanical stresses are most likely involved in the
NH development and its focal nature in the setting of AV
ePTFE grafts. These include blood flow-induced stresses
(for example, low fluid shear stress and increased wall stress
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at the NH-prone site)39,40 and non-flow-induced stresses (for
example, wall stress concentrated at the suture line, increased
wall stress due to compliance mismatch of the elastic native
tissue, and stiff graft/suture material).41,42
Low fluid shear stress. All cells in the vessel wall are
constantly exposed to three types of blood flow-induced
mechanical stresses (Figure 3). (a) As the blood travels in the
vessel lumen, blood pressure exerts a stress perpendicular to
the vessel wall. (b) Stretching of the compliance vessel wall by
the transmural pressure gradient causes circumferential wall
stress, which is also known as ‘hoop stress’ or simply ‘wall
stress’.43 (c) Fluid wall shear stress, or simply ‘shear stress’, is
the friction at the interface between luminal flowing blood
and the apical surface of endothelial cells. Normally, only
endothelial cells are directly exposed to luminal flow. In the
event of denudement of the endothelial layer, however, SMC
and even fibroblasts can be exposed directly to luminal flow.
This can occur after surgical trauma such as AV grafting. These
three types of hemodynamic stresses regulate the function and
dynamic remodeling of the vascular wall, and also contribute
to the development of pathological conditions.44–48
In contrast to that in a large straight vessel, blood flow is
not laminar in the NH-prone sites of the graft–venous
anastomosis and the juxta-anastomotic downstream venous
segment. Blood flow in these regions is far more complex and
is characterized by flow separation (or flow split), stagnation,
vortices (or eddies), turbulent flow, and low shear stress in
different areas (Figure 4).49–53 Detailed flow information in
these regions remains to be characterized, and the majority of
available flow data are derived from flow rates measured at a
few locations near or outside the anastomosis.39 Loth et al.54
used a realistic reconstruction of a canine iliofemoral PTFE
graft model and computational fluid dynamic models, based
on in vivo and in vitro hemodynamic measurements, to show
an inverse correlation between wall shear stress and NH
formation.
A strong association between low shear stress and
atheroma formation with SMC proliferation was first
proposed in 1969.55 Since then, numerous subsequent cell
culture, animal, and clinical studies have confirmed that
physiologically high shear stress inhibits SMC proliferation,
whereas low shear stress promotes SMC proliferation.56–60
High shear stress may inhibit arterial SMC proliferation by
upregulating transforming growth factor-b1 in an autocrine
manner,60,61 whereas low shear stress induces arterial SMC
proliferation by upregulating PDGF.56,57 It is unclear,
however, if these findings are applicable to venous SMC.
This question is important, as stenosis occurs more often at
the venous than at the arterial anastomosis of the AV ePTFE
graft. Furthermore, the complex flow pattern in the
graft–venous anastomosis and the juxta-anastomotic seg-
ments exposes cells to abnormal temporal and spatial shear
stress gradients. Although vein-wall vibration caused by flow-
mediated turbulence has been associated with enhanced
mitogen-activated protein kinase activities in a porcine AV
PTFE graft model,62 the effects of complex flow on arterial or
venous SMC are not completely known.63
In addition to its influence on SMC, low fluid shear stress
may enhance the entrapment of platelets and leukocytes to
the vessel wall in these regions.64 It is, however, controversial
as to what level of fluid shear stress can entrap or activate
circulating blood cells in vivo.65–71
Increased wall stress. Increased tensile wall stress at the
graft anastomosis can result from several mechanisms. The
blood pressure and wall stress in veins are on the order of 103
and 104 Pa, respectively, in healthy individuals.43 In the
venous side of an AV graft, however, these values can increase
10-fold to levels that are comparable to arterial blood
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Figure 3 | Diagram of the major hemodynamic stress forces on
the vascular cell. The forces acting on a cell can be described in
terms of pressure or stress, which is defined as force per unit area,
for example, pascal (Pa). The stress is ‘shear’ when the force is
applied parallel to the area and ‘normal’ when the force is
perpendicular to the area. Major hemodynamic stress forces
include fluid shear stress, circumferential stress, and blood
pressure. The latter two are normal stresses.
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Figure 4 | Modeled blood flow at the venous anastomosis of
an AV graft. A three-dimensional volumetric figure was
reconstructed from an MR image of the venous anastomosis of
the AV graft in a porcine model. Flow patterns were
computationally modeled within the graft geometry using flow
velocity values derived from cine-phase contrast MRA
measurements in the graft at the anastomosis and outflowing
vein. The blood flow velocity magnitudes were scaled relative to
the peak magnitude of the velocity in the graft. These data
indicate that flow at the venous anastomosis is very complex both
in velocity (as indicated by the wide range in velocity) and in flow
path (as indicated by the retrograde flow in the distended region
of the distal segment).
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pressure (104 Pa) and arterial wall stress (105 Pa). There is a
further elevation of wall stress at the graft-vessel anastomosis
due to the compliance difference between the elastic native
tissue and the less compliant graft and suture materials that is
present in both arterial and venous sides of an AV ePTFE graft.
A relatively larger increase in wall stress in the venous side may
render it more susceptible to NH than the arterial side.
In contrast to the inverse relationship between fluid shear
stress and cell proliferation, there is a positive, although
nonlinear, relationship between tensile wall stress and cell
proliferation.72–75 Although some investigators have ques-
tioned whether the enhanced proliferation is a result of
increased stress or the ensuing increased stiffness,76–78 it is
generally accepted that wall stress induces cell proliferation.
From an engineering perspective, under normal conditions,
cells appear to counteract an increase in tensile wall stress by
increasing the tissue mass, thereby maintaining stress home-
ostasis. Such an adaptation is, however, not always beneficial
and may contribute to pathological states. An example of this
maladaptation is cardiac and vascular hypertrophy that is
caused by chronic arterial hypertension.79 Numerous cell
culture and animal studies have identified the growth factors
and their receptors, signal transduction pathways, and
immediate genes that may participate in wall stress-induced
arterial SMC proliferation. These studies generally showed
that increased tensile wall stress activates a transcription
factor that reacts with a strain-responsive element in the
promoter region of the PDGF gene,80 PDGF receptors,81,82
mitogen-activated protein kinase-mediated pathways,83–90
the prosurvival Akt pathway,91,92 and adenylyl cyclase93 in
arterial SMC. It is also unclear whether these findings are
applicable to venous SMCs. Furthermore, in addition to
circumferential wall stress, stretching of the blood vessel wall
also may result in longitudinal and radial wall stress, but their
effects on SMC are unknown.
IMAGING NH
Color Doppler ultrasonography
A number of imaging modalities are available for the
evaluation of the hemodialysis AV graft. Color Doppler
Ultrasonography (CDUS) is often the first-line method in the
clinic, because it is noninvasive, widely available, and
relatively inexpensive. CDUS provides the blood flow rate
and the luminal diameter. However, operator skill can greatly
influence the quality of images.94 In addition, CDUS does not
detect the stenoses in central veins that are below the clavicle
and can overestimate the stenotic lesions in the arterial
anastomoses.95 CDUS also does not provide as complete a
global map of the vascular system as other techniques.
However, Bacchini et al.96 reported the successful use of
CDUS to guide the angioplasty of stenotic lesions in
hemodialysis grafts.
Contrast digital subtraction angiography
Digital subtraction angiography (DSA) is the current gold
standard for vascular access imaging and for guiding
angioplasty. DSA provides a global and detailed vascular
map of the lumen in a single plane. However, DSA exposes
the patient to nephrotoxic radiocontrast agents and to
radiation. In addition, as DSA provides only information
about the vessel lumen but not the wall, vessel spasm that
occurs spontaneously or induced by contrast can influence
stenosis findings.
Magnetic resonance imaging
Magnetic resonance (MR) imaging techniques such as three-
dimensional (3D) contrast-enhanced MR angiography
(MRA), time-of-flight angiography, and cine phase-contrast
angiography have been investigated for utility in preoperative
vein mapping as well as hemodialysis AV graft surveil-
lance.97,98 A detailed review of the utility of MR imaging in
hemodialysis access management has been published.97 MR
techniques can provide 2D (two-dimensional) and 3D images
in any orientation, as well as blood flow information. The
quality of images obtained by 3D contrast-enhanced MRA,
and interobserver agreement on stenosis, have been reported
to be superior to those obtained by DSA,99 but it also results
in a higher number of false-positive stenotic lesions
compared with DSA, presumably because of the complex
flow patterns induced by the configuration of the conduit.
The major drawbacks of MRA for AV graft surveillance in the
clinic are the expense, and the risks of developing
nephrogenic systemic fibrosis from gadolinium-based con-
trast exposure.100
Magnetic resonance techniques can be very useful for
research purposes. For example, we have recently obtained
high-resolution images of NH lesions in our porcine AV graft
model using MR without contrast.101 This technique allows
the in vivo quantification of the NH volume with repeated in
vivo assessments over time that can be used as end points in
the development of strategies to inhibit NH. Second,
velocity-encoded cine phase-contrast MRA can provide
highly resolved through-plane flow velocity patterns, and
specific in-plane velocity patterns, in addition to blood
volume flow rates. Fluid wall shear stress can then be
calculated from the space-averaged through-plane flow
velocity. Misra et al.102 recently used cine-phase contrast
MRA to show immediate and long-term increases in fluid
wall shear stress at a location 2 cm distal to the venous
anastomosis of a porcine iliac artery-to-iliac vein ePTFE graft
model. However, these data do not provide information
about flow at the anastomosis itself where NH appears, or
within other regions of the vein. We have used computational
fluid dynamic modeling to more completely predict flow
patterns in our porcine AV graft model. In these preliminary
studies, a 3D volumetric reconstruction of a graft-vein
anastomosis was derived from an in vivo MR image. Inflow
values within the ePTFE graft were collected on the same
animal using cine phase-contrast MRA. Computational fluid
dynamic modeling was then used to predict flow patterns on
the basis of these in vivo values (Figure 4). These studies
predict very complex flow patterns at the venous anastomosis
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and the juxta-anastomotic regions of the vein. Analyzing
such flow maps over time should help to further determine
the effects of blood flow on NH development and vice versa
in specific locations of AV grafts.
Intravascular ultrasound
With intravascular ultrasound (IVUS), an ultrasound trans-
ducer is introduced into the vascular access lumen and pulled
along the vessel’s length, whereupon images of the vessel wall
are obtained. Arbab-Zadeh et al.103 reported that IVUS was
more sensitive than contrast angiography in detecting
thrombus and graft deterioration from repeated needle
puncture (roughening of luminal surface) in hemodialysis
AV grafts. As it yields multiplane images, IVUS provides a
more complete assessment of luminal diameters than DSA,
which only provides a single-plane image of the vessel lumen.
Multiplane images are advantageous because the cross-
sections of veins are typically elliptical in shape; further,
NH may not involve the complete circumference of the
vessel.
Intravascular ultrasound has been found to be useful for
evaluation of AV graft NH in animal models.104–106 Using this
technique, the intima, media, and adventitia of the arterial
wall can be delineated. IVUS images of calcified regions of
the vessel wall have been reported to correlate well with
calcium quantification obtained by histological staining.107
A disadvantage is that IVUS provides only limited spatial
resolution, making it difficult to determine the exact location
of the obtained images along the length of the vessel. Precise
spatial resolution can be obtained if the progression of the
ultrasound transducer is tracked by simultaneous biplane
angiography so that the IVUS images can be aligned with the
vessel length.108 However, this dual technique involves
exposure of the patient to contrast and radiation and at this
time is too complicated and expensive to be justified
clinically.
Computerized tomography
Recently, findings of AV fistula stenosis using multislice
computerized tomography (CT) angiography were shown to
correlate well with those obtained by DSA.109.Ko et al.110
reported that multidetector CT had high sensitivity com-
pared with DSA in detecting stenotic lesions in AV fistulas
and grafts. The production of 3D images is one advantage of
CT scanning over DSA and CDUS. However, exposures to a
significant amount of radiation and to iodinated contrast
agents are disadvantages of CT scanning, similar to DSA.
TREATMENT USING ANGIOPLASTY
The current clinical treatment for AV graft stenosis is mainly
percutaneous transluminal angioplasty (PTA). Early studies
demonstrated that PTA was an effective treatment for all
types of venous stenoses.7,111 Beathard111 reported an initial
success rate of 94% and primary patency rates at 90, 180, and
360 days of 90.6, 61.3, and 38.2%, respectively. Although PTA
often improved the blood flow, at least temporarily, the
vascular wall injury produced by the balloon promotes
hyperplasia and further stenosis, as seen in postangioplasty
coronary restenosis.112 Histologically, markedly increased cell
proliferation activity has been found in postangioplasty
restenotic lesions of AV fistula,113 which was much higher
than that observed in primary stenotic lesions. In one clinical
observational study, the 360-day primary patency rate of
forearm synthetic AV grafts was 40%, but after the second
angioplasty, the patency rate was only 25%. The 180-day
patency rate following the third angioplasty was 0%.12 This
accelerated time course to stenosis after consecutive angio-
plasty procedures suggests that angioplasty promotes NH
formation. Indeed, most randomized clinical trials failed to
demonstrate a benefit of routine monitoring of AV grafts
with prophylactic PTA of stenotic lesions.114–117
To overcome the restenosis induced by PTA, various
mechanical devices have been employed. Early clinical studies
using bare metallic stents in conjunction with PTA have,
however, yielded limited success because of the development
of in-stent stenosis (that is, the ingrowth of neointimal
hyperplasic tissue through the mesh of a metallic stent).118 A
recent retrospective study examined in 51 patients the
efficacy of stents made of nitinol or PTFE-encapsulated stent
grafts for the treatment of hemodialysis graft-related stenosis
that had previously failed PTA. None of the stents used in
that study were drug-eluting stents. Following PTA and
insertion of the device, the primary patency of the nitinol
stent or stent graft was 87% at 6 months, although the
primary patency of the entire vascular access was only
54%.119 A control group was not available for comparison in
that study. Drug-eluting stents have been shown to be useful
for the prevention of coronary restenosis induced by PTA. In
a porcine AV ePTFE graft model, rapamycin-eluting stents
have also been shown to significantly reduce NH and increase
graft diameter and blood flow rate, compared with unstented
grafts or grafts treated with bare-metal stents.120 There are,
however, no clinical data using drug-eluting stents in
conjunction with PTA to treat venous stenosis in hemodia-
lysis vascular access.
PREVENTION STRATEGIES
The following discussion will explore approaches for NH
prevention, although some of these approaches could also be
potentially useful for regression of existing lesions (Table 1).
The significant progress that has been made in the under-
standing of its pathogenesis has led to the successful
employment of a number of agents to inhibit NH in various
animal models, including some specifically in the hemodia-
lysis AV graft setting. No therapy has proven effective in
hemodialysis patients with AV grafts, although clinical trials
conducted so far have been very limited.
The optimum duration of the therapy would partly
depend on the duration in which the graft is at risk for NH
development. Foreign-body response, aberrant mechanical
forces on the vascular wall, and repeated needle puncture are
likely important on-going stimuli in the hemodialysis AV
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graft setting. This is in contrast to angioplasty-induced NH in
the coronary artery, in which the insult is transient.
Therefore, preventive therapies would ideally be continuous,
as can theoretically be accomplished by the sustained release
of a drug from a replenishable depot. Modification of the
graft material or mechanical environment is also an attractive
approach to inhibit NH development.
Mechanical design
Expanded PTFE, polyethylene terephthalate (for example,
Dacron), and polyurethane are the major materials currently
used for vascular prosthesis.121,122 ePTFE is preferred in part
because of better surgical handling and lower rate of
disintegration.122,123 ePTFE is a porous fluoropolymer
produced by thermomechanical stretching, and its micro-
structure consists of interspaced solid nodes interconnected
by small fibrils. The pore sizes average on the order of 30 mm
on the lumen surface in vascular applications. The addition
of an external radial support (for example, coil or rings)
enhances graft stability against compression and prevents
kinking at points of angulation.
Although ePTFE grafts have been used for many years,
several problems remain. For example, because of the node-
fibril structure, acute sealing of suture is difficult until tissue
ingrowth occurs to cover its surface. Furthermore, such
microporous tubular structures tend to exhibit low axial tear
strength, so that a small tear tend to propagate along the axial
length of the tube. These problems can be reduced by
decreasing the pore size or density. However, smaller pore
size inhibits tissue ingrowth through the pores, thus delaying
integration of the graft with the surrounding vascular tissue
and decreasing the compliance of the graft, which would
exacerbate the elasticity mismatch.124–126
Elasticity mismatch between the stiff ePTFE graft and
elastic native tissue is another major mechanical problem.
The elastic modulus (or elastic stiffness) of the ePTFE graft
wall is 4.06 109 Pa, which is 1.6 times higher than the
human coronary artery.127 Increasing the pore size and
density can increase the compliance of the graft and enhance
tissue ingrowth, but only at the expense of reducing overall
tensile strength and the ability for the graft to retain sutures.
Iterations of ePTFE (for example, a composite of ePTFE and
polyurethane128) have been studied, but their usefulness
remains to be explored.
Currently, the main approach to solve the elastic
mismatch problem is to use natural, instead of synthetic,
material such as decellularized xenografts. Several hemodia-
lysis grafts of bovine origin are available commercially.
Modified bovine carotid artery grafts have been used since
the 1970s before ePTFE became available. Most retrospective
studies suggest that ePTFE grafts are superior to bovine
artery grafts because the former are associated with less
infection and thrombosis and have a longer patency
period.129–144 Decellularized xenografts made from bovine
mesenteric veins145–148 or bovine ureters149,150 have become
available recently. Some clinical studies have suggested that
these new bovine grafts may offer a safe alternative to
patients who have a history of failed ePTFE grafts, but
data are very limited.145 The major disadvantages of the
bovine grafts include a lower overall mechanical strength and
more difficulty to repair when compared with synthetic
grafts.
Table 1 | Preventive strategies for neointimal hyperplasia associated with synthetic hemodialysis AV grafts
Strategy Mechanism of action
Used in AV graft
model (citation)
Mechanical design
Tapered graft and precuffed graft Improve the geometry at anastomosis Yes152–158
Decellularized xenograft Improve elastic mismatch between graft and native vessel Yes145–150
Biological reagents
Antisense ODNs Inhibit DNA transcription, production of mRNA, and synthesis of various
proteins
No
Decoy (E2F) Inhibit cell-cycle progression Yes11
Gene transfer
VEGF Promote endothelialization No
C-type natriuretic peptide Inhibit proliferation through cGMP induction Yes178
Cell-based therapies
Endothelial progenitor cells Promote endothelialization of the graft surface Yes180
Endothelial cell implant using gelfoam matrices Promote endothelial function Yes181
Small-molecule drugs
Rapamycin Inhibit protein translation Yes120
Paclitaxel Inhibit mitosis by stabilizing microtubules Yes15,183,184,198
Dypiridamole Inhibit phosphodiesterase activity Yes204
Imatinib methylate Inhibit PDGF receptor activity No
Irradiation Induce DNA damage Yes223–225
AV, arteriovenous; cGMP, cyclic guanosine monophosphate; ODN, antisense oligonucleotide; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
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Expanded polytetrafluoroethylene grafts with various
configurations have been designed to improve the geometry
at the anastomosis, thereby improving the blood flow
patterns. A commercially available modified ePTFE graft
reinforced by a proprietary, cross-helical nonporous ePTFE
yarn wrap that covers 70% of the external graft surface, was
proposed to enhance flow dynamics by preserving the graft
luminal shape. Unfortunately, this design did not prolong the
graft patency in a clinical study.151 Another approach is to
use tapered instead of straight ePTFE grafts, where the graft’s
luminal diameter decreases gradually from the venous end to
the arterial end. Such a design is based on the consideration
that diameter mismatch is an important factor contributing
to abnormal flow patterns at the anastomoses. Limited
clinical studies suggested that 8- to 6-mm tapered grafts
improved primary patency rate and decreased complications,
compared with 6-mm straight grafts. Further studies are
required to confirm these observations.152,153 Yet another
approach is to create a cuffed geometry made of ePTFE at the
venous anastomosis to reduce regional turbulence, as venous
cuffs seems to be beneficial in the arterial–arterial bypass
ePTFE graft setting. However, it has been suggested that the
benefit associated with the vein cuff may be related to the
presence of venous material, with improved wall compliance
matching and other biological factors, rather than altered
anastomotic geometry and hemodynamics, as CFE showed
that anastomotic hemodynamics are unchanged or worsened
when vein cuffs are used.154–156 Another disadvantage of the
precuffed ePTFE graft is that it does not provide surgeons the
flexibility to trim the cuff to fit the native vessel during
implantation. The cuff also increases the surface area that
needs suturing, which in turn increases suture-line wall stress.
Results from clinical studies comparing the cuffed and
standard ePTFE hemodialysis grafts are conflicting.157,158
Surgical methods, such as suturing techniques41 and the
angle of anastomosis,159 may play a role in attenuating the
compliance mismatch problem.
Biological reagents
Antiproliferative drugs and biological reagents used to
prevent NH can be delivered either systemically or locally.
As NH is usually focal, although sometimes multifocal, and is
relatively small and not malignant, local therapy is preferred
because it would achieve a much higher concentration at the
target site with far fewer systemic side effects than systemic
therapy. A number of biological reagents have been examined
for efficacy against NH development in AV grafts, including
transfection of vessels with gene constructs that are
antiproliferative and seeding of endothelial cells to grafts.
Antisense oligonucleotides. Antisense oligonucleotides
(ODNs) can be used to inhibit DNA transcription, the
production of mature mRNA, and protein synthesis.
Antisense ODNs directed against a number of proto-
oncogenes and cell-cycle regulators, such as c-myc, c-myb,
proliferating cell nuclear antigen, nuclear factor-kB, or
different cyclin-dependent kinases, have been used to inhibit
NH in arterial injury models.160–163 However, a clinical trial
of intracoronary administration of antisense ODNs against
c-myc immediately after coronary stenting failed to demon-
strate the prevention of in-stent restenosis.164 There is no
information on the usage of antisense ODN in AV graft
models.
E2F decoy. Directly targeting E2F, a family of transcrip-
tion factors important in cell replication, by using decoy
ODNs that bind E2F (E2F decoy) prevented NH in balloon-
injured carotid arteries and vein interposition grafts in
animal models.165–167 Earlier randomized trials conducted in
patients undergoing peripheral arterial bypass (PREVENT I)
or coronary arterial bypass (PREVENT II) grafting with
autologous veins have demonstrated the feasibility, safety,
and efficacy of using E2F decoy to prolong patency.168,169.
Subsequent larger randomized multicenter phase III trials,
PREVENT III170 and PREVENT IV,171 failed to confirm the
efficacy of E2F decoy in preventing vein bypass stenosis. A
phase II clinical trial using E2F decoy to decrease NH in
hemodialysis AV grafts is currently in progress.
Gene transfer. As surgical manipulation causes damage to
the endothelium and the endothelium is important in
regulating SMC growth, it has been hypothesized that rapid
re-endothelialization of the vascular wall after injury may
reduce restenosis. VEGF is a growth factor family that
induces endothelial cell proliferation and migration.172
Intravascular adenovirus-mediated VEGF-C gene transfer
reduced NH in balloon-denuded rabbit aorta.173 In a rabbit
carotid artery collar model, however, adventitial delivery of
adenoviruses encoding VEGF-A and VEGF-D increased,
rather than decreased, NH.174 Recently, ePTFE grafts coated
with VEGF-A in a fibrin matrix interposed in pig carotid
arteries were also found to enhance NH.175 Thus, maneuvers
that are designed to inhibit NH by promoting endothelializa-
tion have yielded conflicting results. The effect of local
delivery of VEGF by gene transfer has not yet been explored
specifically in AV ePTFE grafts.
C-type natriuretic peptide is an endothelium-derived
peptide with antiproliferative effects on SMC through the
induction of cyclic guanosine monophosphate.176 Adeno-
virus-mediated gene transfer of C-type natriuretic peptide
was shown to inhibit NH in a rabbit jugular vein inter-
positional graft model.177 In a porcine AV ePTFE graft model,
however, local overexpression of C-type natriuretic peptide
enhanced venous medial thickening but failed to inhibit
NH.178 In another study, transduction of the external jugular
vein with an adenoviral vector overexpressing the carboxyl
terminus of the b-adrenergic receptor kinase, an inhibitor of
G-protein signaling, significantly reduced NH at the venous
anastomosis in a porcine AV ePTFE graft model.179
Cell-based therapies. Several groups have reported cell-
based therapies to inhibit NH in AV ePTFE graft models. In a
porcine AV ePTFE graft model, Rotmans et al.180 evaluated
the feasibility of capturing endothelial progenitor cells in vivo
using anti-CD34 antibodies immobilized on ePTFE grafts.
Despite the successful endothelialization using this technique,
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NH at the venous anastomosis increased substantially,
instead of decreased, at 4 weeks after implantation.180 In
another porcine AV ePTFE graft study, gelfoam matrices
containing allogeneic porcine aortic endothelial cells were
applied around the anastomoses and outflow vein. At 28 days
after graft placement, venous lumen diameter and positive
remodeling were increased, but no significant decrease in NH
was observed.181 These studies raise skepticism regarding the
value of promoting endothelialization or endothelial func-
tions in preventing NH.
Small-molecule drugs
If successful, small-molecule drugs have an advantage over
biological reagents because they are simpler and less likely to
elicit host immunological responses. Local drug delivery can
be achieved using several approaches: (1) coating of the graft
with the drug; (2) placing a drug-coated stent intravascularly
at the anastomosis; (3) injecting the drug into the vascular
wall at the anastomoses through an intravascular catheter;
(4) placing a drug depot perivascularly at the anastomoses.
The latter has been accomplished by the placement or
injection of a polymer gel containing the drug15,182 or placing
the drug in an impermeable wrap that encases the
anastomoses.183,184 Hypothetically, the perivascular approach
has a particular advantage because the drug will be in close
proximity to the adventitial fibroblasts, which are considered
to be critical for NH formation. Below are several
antiproliferative drugs that have demonstrated efficacy in
inhibiting NH in arterial-injury animal models. Some of
these drugs have also been tested in AV ePTFE graft models
by our group and other investigators.
Rapamycin (sirolimus). Rapamycin is a macrocyclic triene
antibiotic used clinically to inhibit T-lymphocyte activation
and prevent allograft rejection. Rapamycin was also reported
to inhibit vascular SMC proliferation after balloon angio-
plasty.185–187 Rapymycin-coated stents have been shown to be
effective in decreasing major adverse cardiac events and
restenosis rates after angioplasty in patients with coronary
disease (RAVEL, SIRIUS trials).188–191 In a porcine AV ePTFE
graft model, rapamycin-eluting stents significantly reduced
NH and increased graft diameter and blood flow rate,
compared with unstented grafts or grafts treated with bare-
metal stents.120 Although these studies are promising, this
approach requires an invasive procedure of placing a stent.
Furthermore, drug release from coated stents is of a limited
duration. The inability to replenish the drug depot in the
stent may diminish the effectiveness of this strategy in
preventing NH development in AV grafts in which the stimuli
are chronic. There are no clinical trials reported to date on
hemodialysis AV grafts using rapamycin-coated stents.
Paclitaxel. Paclitaxel inhibits cell division through stabi-
lization of the mitotic spindle.192 Local administration of
paclitaxel by use of microporous intravascular balloons
prevented NH formation in a rabbit carotid arterial-injury
model.193 Several clinical trials (TAXUS I, ELUTES, ASPECT,
TAXUS IV trials) have established the safety and efficacy of
paclitaxel-coated stents in preventing restenosis in coronary
arteries.194–197 Data from our laboratory demonstrated that
the perivascular sustained delivery of paclitaxel at the
anastomoses using a polymer gel could inhibit NH in a
canine AV ePTFE graft model.15 Coating of ePTFE grafts with
paclitaxel has also been demonstrated to inhibit NH in a
porcine model of AV graft stenosis, compared with uncoated
grafts.198 Recently, paclitaxel-eluting wrap placed around the
anastomoses was reported to inhibit NH formation in
sheep183 and porcine184 AV ePTFE graft models. Clinical
trials testing the efficacy of local delivery of paclitaxel using
any technique have not been reported in hemodialysis AV
grafts to date.
Dipyridamole. In addition to antiplatelet activity, dipyr-
idamole also inhibits SMC proliferation in vitro, although the
concentrations required for inhibition (IC50 values) are
approximately 1000-fold higher than those of rapamycin
and paclitaxel.199,200 A small clinical trial has suggested the
efficacy of oral dipyridamole in decreasing PTFE graft
occlusion in dialysis patients,201 but stenosis was not
specifically examined in that study. A large multicenter trial
sponsored by the National Institutes of Health using the oral
combination of dipyridamole and aspirin in preventing AV
graft failure in dialysis patients is ongoing. Continuous
adventitial dipyridamole delivery using an osmotic pump
inhibited NH formation in rabbit artery-injury models.202 In
contrast, there was no significant decrease in restenosis rates
after coronary angioplasty using intracoronary dipyridamole
in a small randomized clinical trial.203 Furthermore, in our
porcine AV ePTFE graft model, local perivascular sustained
delivery of dipyridamole using a polymer gel applied at the
anastomoses, even at high dosages, was ineffective in
inhibiting NH.204 This ineffectiveness of local delivery of
dipyridamole may be due to the relatively low antiprolifera-
tive potency of the drug against vascular SMC, the short
duration of release of the drug from the polymer gel because
of the hydrophilic nature of the drug, or other factors.
Imatinib mesylate. Platelet-derived growth factor and its
receptors are prominently expressed in NH lesions of human
vascular diseases and animal models. Previous studies have
demonstrated the efficacy of PDGF antibodies or PDGF-
receptor antagonists in the prevention of NH in animal
models of arterial injury or interposition grafts.205,206
Therefore, targeting PDGF and PDGF receptors is a logical
strategy for NH inhibition associated with hemodialysis AV
grafts. Imatinib mesylate is a low-molecular-weight inhibitor
of the phosphotyrosine kinase activity of both PDGF receptor
subtypes,207 as well as that of Bcr-Abl208 and c-kit.209
Imatinib is currently used clinically to treat several forms
of malignancies.210,211 The therapeutic efficacy of imatinib
has also been demonstrated in animal models of arterial
proliferative diseases, including restenosis after balloon
angioplasty,212 diet-induced atherosclerosis,213 and post-
transplant atherosclerosis of heart and aorta.214 Recently,
oral imatinib has been shown to potentiate the effect of local
intravascular transfection with the VEGF-C gene in reducing
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NH in hyperpcholesterolemic rabbits.215 Data from our
laboratory demonstrated the inhibitory effect of imatinib on
both human arterial and venous SMC in vitro, with the IC50
values being eightfold lower in the venous cells than in the
arterial cells.216 Imatinib is therefore a promising drug for the
prevention of hemodialysis AV graft stenosis.
Irradiation
In recent years, there has been intensive research on the use of
ionizing radiation for inhibition of NH. The main effect of
vascular brachytherapy appears to be mediated by irradiation-
induced DNA damage of vascular cells with consequent arrest
at the G1 checkpoint and induction of apoptosis through p53-
induced p21 upregulation.217 Results from various animal
models have clearly established that beta or gamma ionizing
radiation inhibits restenosis after angioplasty.218–220 Several
clinical trials have also shown that intracoronary radiation is
safe and effective for treatment of restenotic coronary arteries
after angioplasty.221,222 In a porcine model of hemodialysis AV
grafts, local delivery of gamma radiation reduced NH at the
venous anastomosis.223 Despite these encouraging data, recent
clinical trials in hemodialysis patients failed to demonstrate
significant inhibition of stenosis by radiation treatment of
native AV fistulas or ePTFE grafts.224,225
CONCLUSION
The pathogenesis of NH associated with hemodialysis AV
grafts is complex and likely involves surgical manipulation of
the tissues, material bioincompatibility, and mechanical
factors, which could be aggravated by angioplasty of the
stenosis. In contrast to post-coronary angioplasty restenosis,
the chronic nature of the stimuli in the AV graft likely requires
strategies that provide chronic prevention. A large number of
antiproliferative and immunomodulating agents are already
in use clinically for various proliferative and immunological
disorders. Adoption of these agents, with the appropriate
delivery platform, technique, and schedule, would likely be
successful in preventing, and perhaps regressing, NH. As
stenosis, and consequentially occlusion, is the predominant
cause of AV graft failure, successful prevention of this
complication should make synthetic grafts a superior mode
of hemodialysis vascular access to complement native fistulas.
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